In a second-quarter meeting with the FDA, Scynexis Inc. will be talking about three mild to moderate thrombotic events in healthy phase I volunteers, and CEO Marco Taglietti told BioWorld Today that the company was already putting together a data package when informed by regulators that no further trials will be allowed with the intravenous (I.V.) form of the antifungal SCY-078 until questions are resolved.